Total
0
Shares
Telix Pharmaceuticals (ASX:TLX) - CEO, Dr. Christian Behrenbruch - The Market Herald
CEO, Dr. Christian Behrenbruch
Source: Twitter
  • Telix Pharmaceuticals (TLX) has recieved $11.4 million from a government-led research and development rebate
  • The grant, received today, covers research and development work Telix completed in Australia and overseas last year
  • It forms part of a wider tax refund scheme, awarded in 2018, which allows Telix to claim up to $55.2 million in rebates over five years
  • The biopharmaceutical company is currently developing technology which uses Molecularly Targeted Radiation (MTR), a technique that binds radioactive payloads directly to a patient's tumour so it can be imaged
  • News of the rebate pushed Telix shares 1.14 per cent into the green in late trade
  • Stock is now priced at $1.33 per share in a $334 million market cap

Telix Pharmaceuticals (TLX) has netted $11.4 million from a government-led research and development (R&D) grant.

The grant, received today, covers research and development work Telix completed here and overseas last year. It forms part of a wider tax refund scheme, awarded in 2018, which allows Telix to claim up to $55.2 million in rebates over five years.

“The Australian Federal Government’s R&D tax credit scheme is of significant value to a late clinical-stage company such as Telix," CFO Doug Cubbin said.

"The return of funds to the company under the R&D tax credit scheme materially augments Telix’s ability to deliver its numerous research partnerships and drug development programs both at home in Australia and abroad," he continued.

The biopharmaceutical company is currently developing technology which uses Molecularly Targeted Radiation (MTR), a technique that binds radioactive payloads directly to a patient's tumour so it can be imaged.

News of the rebate pushed Telix shares 1.14 per cent into the green in late trade. Stock is now priced at $1.33 per share in a $334 million market cap.


Subscribe


TLX by the numbers
More From The Market Herald
Telix Pharmaceuticals (ASX:TLX)- CEO, Dr. Christian Behrenbruch - The Market Herald

" Telix Pharmaceuticals (ASX:TLX) submits NDA for prostate cancer imaging product

Telix Pharmaceuticals (TLX) has submitted a new drug application (NDA) with the U.S.
Recce Pharmaceuticals (ASX:RCE) completes $27.95M capital raise

" Recce Pharmaceuticals (ASX:RCE) completes $27.95M capital raise

Recce Pharmaceuticals (RCE) has completed its capital raise and successfully raised $27.95 million.
Cynata Therapeutics (ASX:CYP) - Managing Director & CEO, Dr Ross Macdonald - The Market Herald

" Cynata Therapeutics (ASX:CYP) receives positive results for stem cell treatment in heart attack

Cynata Therapeutics (CYP) has received positive results for its Cymerus stem cell treatment in a preclinical heart attack model.
PharmaAust Limited (ASX:PAA) - Executive Chairman, Dr Roger Aston - The Market Herald

" PharmAust (ASX:PAA) advances testing against COVID-19

PharmAust (PAA) has advanced its monepantel drugs testing against COVID-19, in the race to find a vaccine for the virus.